The Asia Pacific Advanced Therapy Medicinal Products CDMO Market would witness market growth of 16.9% CAGR during the forecast period (2022-2028).
The market is expanding for two key reasons, an increase in cancer incidence and an increase in funding for R&D in oncology gene therapy activities. Additionally, supportive government regulations for treatment are expected to foster a number of opportunities that will propel the market throughout the course of the forecast year.
A new gene will incorporate into the genome of the patient and proceed to function without compromising with the functions of other genes, which lowers the risk of gene therapy developed for oncology. Advanced therapy medicinal products CDMO market has also been fueled by the continued development of products for sophisticated therapies. These market changes are a result of the increasing demand for products.
During the projection period, it is expected that increasing product demand will create rapid advancements in gene and cell therapies. Biopharmaceutical businesses have recently placed more emphasis on outsourcing manufacturing services to CDMOs. Outsourcing some of the production and development activities enables research organizations and drug developing companies to focus on core and relevant competencies.
The regional market participants would be able to expand their offers and secure the largest possible revenue share attributable to the expanding healthcare infrastructure and enhanced government initiatives. As disposable incomes expand in emerging economies and the region's healthcare infrastructure advances it would increase access to novel treatment options. Furthermore, the patient base are especially large in nations like Korea and India. Therefore, it is anticipated that throughout the forecast period, these factors would present new growth opportunities for the participants’ active in the advanced therapy medicinal products CDMO market.
The China market dominated the Asia Pacific Advanced Therapy Medicinal Products CDMO Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $695 million by 2028. The Japan market is estimated to grow a CAGR of 16.2% during (2022 - 2028). Additionally, The India market would experience a CAGR of 17.6% during (2022 - 2028).
Based on Indication, the market is segmented into Oncology, Cardiology, Central Nervous System & Musculoskeletal, Infectious Disease, Dermatology, Endocrine, Metabolic, Genetic, Immunology & Inflammation, Ophthalmology, Hematology, Gastroenterology, and Others. Based on Product, the market is segmented into Gene Therapy, Cell Therapy, and Tissue Engineered & Others. Based on Phase, the market is segmented into Phase I, Phase II, Phase III, and Phase IV. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc. (Patheon, Inc.), AGC Biologics, Inc. (AGC, Inc.), Catalent, Inc., Minaris Regenerative Medicine GmbH (Resonac Holdings Corporation), WuXi AppTec Co., Ltd. (WuXi Advanced Therapies), Lonza Group AG, Celonic AG (JRS PHARMA GmbH & Co. KG), Rentschler Biopharma SE, and Bio Elpida (Polyplus-transfection SA.)
The market is expanding for two key reasons, an increase in cancer incidence and an increase in funding for R&D in oncology gene therapy activities. Additionally, supportive government regulations for treatment are expected to foster a number of opportunities that will propel the market throughout the course of the forecast year.
A new gene will incorporate into the genome of the patient and proceed to function without compromising with the functions of other genes, which lowers the risk of gene therapy developed for oncology. Advanced therapy medicinal products CDMO market has also been fueled by the continued development of products for sophisticated therapies. These market changes are a result of the increasing demand for products.
During the projection period, it is expected that increasing product demand will create rapid advancements in gene and cell therapies. Biopharmaceutical businesses have recently placed more emphasis on outsourcing manufacturing services to CDMOs. Outsourcing some of the production and development activities enables research organizations and drug developing companies to focus on core and relevant competencies.
The regional market participants would be able to expand their offers and secure the largest possible revenue share attributable to the expanding healthcare infrastructure and enhanced government initiatives. As disposable incomes expand in emerging economies and the region's healthcare infrastructure advances it would increase access to novel treatment options. Furthermore, the patient base are especially large in nations like Korea and India. Therefore, it is anticipated that throughout the forecast period, these factors would present new growth opportunities for the participants’ active in the advanced therapy medicinal products CDMO market.
The China market dominated the Asia Pacific Advanced Therapy Medicinal Products CDMO Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $695 million by 2028. The Japan market is estimated to grow a CAGR of 16.2% during (2022 - 2028). Additionally, The India market would experience a CAGR of 17.6% during (2022 - 2028).
Based on Indication, the market is segmented into Oncology, Cardiology, Central Nervous System & Musculoskeletal, Infectious Disease, Dermatology, Endocrine, Metabolic, Genetic, Immunology & Inflammation, Ophthalmology, Hematology, Gastroenterology, and Others. Based on Product, the market is segmented into Gene Therapy, Cell Therapy, and Tissue Engineered & Others. Based on Phase, the market is segmented into Phase I, Phase II, Phase III, and Phase IV. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc. (Patheon, Inc.), AGC Biologics, Inc. (AGC, Inc.), Catalent, Inc., Minaris Regenerative Medicine GmbH (Resonac Holdings Corporation), WuXi AppTec Co., Ltd. (WuXi Advanced Therapies), Lonza Group AG, Celonic AG (JRS PHARMA GmbH & Co. KG), Rentschler Biopharma SE, and Bio Elpida (Polyplus-transfection SA.)
Scope of the Study
Market Segments Covered in the Report:
By Indication
- Oncology
- Cardiology
- Central Nervous System & Musculoskeletal
- Infectious Disease
- Dermatology
- Endocrine, Metabolic, Genetic
- Immunology & Inflammation
- Ophthalmology
- Hematology
- Gastroenterology
- Others
By Product
- Gene Therapy
- Cell Therapy
- Tissue Engineered & Others
By Phase
- Phase I
- Phase II
- Phase III
- Phase IV
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Thermo Fisher Scientific, Inc. (Patheon, Inc.)
- AGC Biologics, Inc. (AGC, Inc.)
- Catalent, Inc
- Minaris Regenerative Medicine GmbH (Resonac Holdings Corporation)
- WuXi AppTec Co., Ltd. (WuXi Advanced Therapies)
- Lonza Group AG
- Celonic AG (JRS PHARMA GmbH & Co. KG)
- Rentschler Biopharma SE
- Bio Elpida (Polyplus-transfection SA.)
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Advanced Therapy Medicinal Products CDMO Market, by Indication
1.4.2 Asia Pacific Advanced Therapy Medicinal Products CDMO Market, by Product
1.4.3 Asia Pacific Advanced Therapy Medicinal Products CDMO Market, by Phase
1.4.4 Asia Pacific Advanced Therapy Medicinal Products CDMO Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Geographical Expansions
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Acquisitions and Mergers : 2019, Jan - 2022, Aug) Leading Players
Chapter 4. Asia Pacific Advanced Therapy Medicinal Products CDMO Market by Indication
4.1 Asia Pacific Oncology Market by Country
4.2 Asia Pacific Cardiology Market by Country
4.3 Asia Pacific Central Nervous System & Musculoskeletal Market by Country
4.4 Asia Pacific Infectious Disease Market by Country
4.5 Asia Pacific Dermatology Market by Country
4.6 Asia Pacific Endocrine, Metabolic, Genetic Market by Country
4.7 Asia Pacific Immunology & Inflammation Market by Country
4.8 Asia Pacific Ophthalmology Market by Country
4.9 Asia Pacific Hematology Market by Country
4.1 Asia Pacific Gastroenterology Market by Country
4.11 Asia Pacific Others Market by Country
Chapter 5. Asia Pacific Advanced Therapy Medicinal Products CDMO Market by Product
5.1 Asia Pacific Gene Therapy Market by Country
5.2 Asia Pacific Cell Therapy Market by Country
5.3 Asia Pacific Tissue Engineered & Others Market by Country
Chapter 6. Asia Pacific Advanced Therapy Medicinal Products CDMO Market by Phase
6.1 Asia Pacific Phase I Market by Country
6.2 Asia Pacific Phase II Market by Country
6.3 Asia Pacific Phase III Market by Country
6.4 Asia Pacific Phase IV Market by Country
Chapter 7. Asia Pacific Advanced Therapy Medicinal Products CDMO Market by Country
7.1 China Advanced Therapy Medicinal Products CDMO Market
7.1.1 China Advanced Therapy Medicinal Products CDMO Market by Indication
7.1.2 China Advanced Therapy Medicinal Products CDMO Market by Product
7.1.3 China Advanced Therapy Medicinal Products CDMO Market by Phase
7.2 Japan Advanced Therapy Medicinal Products CDMO Market
7.2.1 Japan Advanced Therapy Medicinal Products CDMO Market by Indication
7.2.2 Japan Advanced Therapy Medicinal Products CDMO Market by Product
7.2.3 Japan Advanced Therapy Medicinal Products CDMO Market by Phase
7.3 India Advanced Therapy Medicinal Products CDMO Market
7.3.1 India Advanced Therapy Medicinal Products CDMO Market by Indication
7.3.2 India Advanced Therapy Medicinal Products CDMO Market by Product
7.3.3 India Advanced Therapy Medicinal Products CDMO Market by Phase
7.4 South Korea Advanced Therapy Medicinal Products CDMO Market
7.4.1 South Korea Advanced Therapy Medicinal Products CDMO Market by Indication
7.4.2 South Korea Advanced Therapy Medicinal Products CDMO Market by Product
7.4.3 South Korea Advanced Therapy Medicinal Products CDMO Market by Phase
7.5 Singapore Advanced Therapy Medicinal Products CDMO Market
7.5.1 Singapore Advanced Therapy Medicinal Products CDMO Market by Indication
7.5.2 Singapore Advanced Therapy Medicinal Products CDMO Market by Product
7.5.3 Singapore Advanced Therapy Medicinal Products CDMO Market by Phase
7.6 Malaysia Advanced Therapy Medicinal Products CDMO Market
7.6.1 Malaysia Advanced Therapy Medicinal Products CDMO Market by Indication
7.6.2 Malaysia Advanced Therapy Medicinal Products CDMO Market by Product
7.6.3 Malaysia Advanced Therapy Medicinal Products CDMO Market by Phase
7.7 Rest of Asia Pacific Advanced Therapy Medicinal Products CDMO Market
7.7.1 Rest of Asia Pacific Advanced Therapy Medicinal Products CDMO Market by Indication
7.7.2 Rest of Asia Pacific Advanced Therapy Medicinal Products CDMO Market by Product
7.7.3 Rest of Asia Pacific Advanced Therapy Medicinal Products CDMO Market by Phase
Chapter 8. Company Profiles
8.1 Thermo Fisher Scientific, Inc. (Patheon, Inc.)
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 SWOT Analysis
8.2 AGC Biologics, Inc. (AGC, Inc.)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.2.5.2 Acquisition and Mergers:
8.2.5.3 Geographical Expansions:
8.3 Catalent, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional & Segmental Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.5.2 Acquisition and Mergers:
8.4 Minaris Regenerative Medicine GmbH (Resonac Holdings Corporation)
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expenses
8.5 WuXi AppTec Co., Ltd. (WuXi Advanced Therapies)
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental Analysis
8.5.4 Recent strategies and developments:
8.5.4.1 Product Launches and Product Expansions:
8.5.4.2 Acquisition and Mergers:
8.5.4.3 Partnerships, Collaborations, and Agreements:
8.6 Lonza Group AG
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Geographical Expansions:
8.7 Celonic AG (JRS PHARMA GmbH & Co. KG)
8.7.1 Company Overview
8.8 Bio Elpida (Polyplus-transfection SA.)
8.8.1 Company Overview
8.9 Rentschler Biopharma SE
8.9.1 Company Overview
8.9.2 Recent strategies and developments:
8.9.2.1 Partnerships, Collaborations, and Agreements:
8.9.2.2 Acquisition and Mergers:
Companies Mentioned
- Thermo Fisher Scientific, Inc. (Patheon, Inc.)
- AGC Biologics, Inc. (AGC, Inc.)
- Catalent, Inc.
- Minaris Regenerative Medicine GmbH (Resonac Holdings Corporation)
- WuXi AppTec Co., Ltd. (WuXi Advanced Therapies)
- Lonza Group AG
- Celonic AG (JRS PHARMA GmbH & Co. KG)
- Rentschler Biopharma SE
- Bio Elpida (Polyplus-transfection SA.)
Methodology
LOADING...
